Reduced Systemic Corticosteroid Use among Pediatric Patients With Inflammatory Bowel Disease in a Large Learning Health System

Abstract

Objectives: Corticosteroids have long been used to treat inflammatory bowel disease. However, cumulative corticosteroid exposure is associated with adverse effects, particularly in growing children. Professional guidelines recommend steroid-sparing strategies. It remains unknown whether corticosteroid use has decreased in children with inflammatory bowel disease. Methods: We performed retrospective cohort study using data from 2007 to 2018 from the international multi-center ImproveCareNow Network, a pediatric inflammatory bowel disease quality improvement collaborative. Pediatric patients diagnosed with inflammatory bowel disease were included. Patients with missing diagnosis or corticosteroid use data were excluded. We performed serial cross-sectional analyses of period prevalence and used multivariate regression models. Results: 27,321 patients were included (65% Crohn disease, 28% ulcerative colitis, 7% indeterminate colitis). Corticosteroids were used in 10,206 (37%). Corticosteroid use decreased from 28% (2007) to 12% (2018). Black patients received corticosteroids more commonly than white patients. This disparity improved as corticosteroid use decreased in both groups. Most corticosteroid use occurred <120 days after diagnosis. Corticosteroid or 5-aminosalicylate use <120 days after diagnosis predicted later corticosteroid use. Anti-tumor necrosis factor-alpha medication use <120 days after diagnosis was associated with a reduction in corticosteroid use. As corticosteroid use decreased, steroidsparing therapy use increased and height and weight z scores improved, particularly among children with Crohn disease. Despite improvement across the network, variation in corticosteroid usage remains. Conclusions: Corticosteroid use among pediatric patients with inflammatory bowel disease in the ImproveCareNow Network has decreased over time. Racial disparities in corticosteroid use were found, but gradually improved.

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study

“…Cumulative corticosteroid exposure for a prolonged use or repeated courses might cause growth stunting, hyperglycemia, cushingoid characteristics, skin and mood changes, increased infection risk, and decreased bone density in children with IBD (36). In an effort to reduce the utilization and adverse reactions from corticosteroid treatment, current professional guidelines recommend steroid sparing regimens, which can be effective for many people with IBD (37)(38).…”

Clinical outcomes in pediatric inflammatory bowel disease patients: a systematic review of prospective studies

“…This lower use of CS was also observed in other registries: the ICN registry reported a significant decrease of CS use in both UC and CD patients (from 28% in 2007 to 12% in 2018). This steroid‐sparing therapy led to improved height and weight z scores 40 …”

Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies

“…A large cohort study showed that unrelated to the IBD subtype, the administration of biologicals a short time after diagnosis (<120 days) is connected to fewer glucocorticoids being needed [ 32 ]. Another large cohort study of pediatric patients with IBD demonstrated that the early treatment with TNF-α blockers was superior to immunomodulators in achieving remission within three months [ 29 ].…”